Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease.


Journal

Mediators of inflammation
ISSN: 1466-1861
Titre abrégé: Mediators Inflamm
Pays: United States
ID NLM: 9209001

Informations de publication

Date de publication:
2021
Historique:
received: 07 09 2020
revised: 24 12 2020
accepted: 05 01 2021
entrez: 24 2 2021
pubmed: 25 2 2021
medline: 5 11 2021
Statut: epublish

Résumé

Studies on serum leucine-rich alpha-2 glycoprotein (LRG) in inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), are scarce; the methods for estimating disease activity are less established, particularly for CD. This study is aimed at evaluating the utility of serum LRG as a potential inflammatory marker for IBD and to investigate the LRG gene expression in peripheral blood mononuclear cells (PBMCs) as a possible source of serum LRG. Overall, 98 patients with UC and 96 patients with CD were prospectively enrolled and clinically evaluated; 92 age-matched individuals served as the healthy controls. The blood samples were analyzed for serum LRG levels and routine laboratory parameters. Disease activity was assessed clinically and endoscopically. Finally, LRG gene expression in the PBMCs from a different cohort (41 patients with UC, 34 patients with CD, and 30 healthy controls) was examined. The serum LRG levels were higher during active disease than during inactive disease; additionally, serum LRG levels were positively correlated with clinical disease activity, C-reactive protein (CRP) levels, and other laboratory parameters in patients with UC and CD and with endoscopic disease activity in UC. UC and CD showed comparable areas under the curve (AUC) values for determining clinical remission and differentiating between endoscopic remission associated with LRG and CRP. The levels of LRG mRNA were also increased in PBMCs from patients with UC and CD and reflected disease activity. These data suggest that serum LRG, originated partially from PBMCs, is an inflammatory marker in UC and CD. A large-scale well-designed study should be conducted in the future to more accurately reveal the clinical significance of LRG in patients with IBD.

Identifiants

pubmed: 33623482
doi: 10.1155/2021/8825374
pmc: PMC7874844
doi:

Substances chimiques

Biomarkers 0
Glycoproteins 0
LRG1 protein, human 0
C-Reactive Protein 9007-41-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8825374

Informations de copyright

Copyright © 2021 Tetsuhiro Yoshimura et al.

Déclaration de conflit d'intérêts

The authors declare that there is no conflict of interest regarding the publication of this paper.

Références

Mod Rheumatol. 2017 Sep;27(5):833-837
pubmed: 28094589
J Clin Endocrinol Metab. 2017 Oct 1;102(10):3683-3691
pubmed: 28973352
J Gastroenterol Hepatol. 2013 Jul;28(7):1076-86
pubmed: 23489082
Ann Rheum Dis. 2010 Apr;69(4):770-4
pubmed: 19854709
Biochem Biophys Res Commun. 2009 May 15;382(4):776-9
pubmed: 19324010
Gastroenterology. 2015 Oct;149(5):1275-1285.e2
pubmed: 26166315
Gut. 1995 Jan;36(1):45-9
pubmed: 7890234
J Clin Invest. 2007 Mar;117(3):514-21
pubmed: 17332878
Arthritis Rheumatol. 2015 May;67(8):2056-60
pubmed: 25917892
BMC Cancer. 2018 Apr 11;18(1):406
pubmed: 29642865
J Clin Endocrinol Metab. 2015 Apr;100(4):1586-93
pubmed: 25636050
Gastroenterology. 1979 Oct;77(4 Pt 2):847-69
pubmed: 38176
J Dermatol Sci. 2017 May;86(2):170-174
pubmed: 28179066
Gastrointest Endosc. 2004 Oct;60(4):505-12
pubmed: 15472670
Clin Chim Acta. 2019 Oct;497:141-146
pubmed: 31361991
Clin Biochem. 2017 Jun;50(9):485-490
pubmed: 28202345
Sci Rep. 2017 Mar 06;7:43732
pubmed: 28262744
World J Gastroenterol. 2016 Jan 21;22(3):1304-10
pubmed: 26811667
Lancet. 1980 Mar 8;1(8167):514
pubmed: 6102236
Diabetes Metab Res Rev. 2018 Oct;34(7):e3029
pubmed: 29883055
Inflamm Bowel Dis. 2012 Nov;18(11):2169-79
pubmed: 22374925
Circ Heart Fail. 2011 Mar;4(2):188-97
pubmed: 21282491
J Clin Med. 2020 Aug 14;9(8):
pubmed: 32823895
J Gastroenterol Hepatol. 2011 Oct;26(10):1493-9
pubmed: 21777275
Digestion. 1991;50(2):104-11
pubmed: 1804734
Scand J Rheumatol. 2015;44(5):399-403
pubmed: 26079682
Nat Commun. 2018 Apr 25;9(1):1661
pubmed: 29695774
Front Med (Lausanne). 2020 Apr 22;7:123
pubmed: 32391365
N Engl J Med. 1987 Dec 24;317(26):1625-9
pubmed: 3317057
Gastroenterol Jpn. 1991 Feb;26(1):20-8
pubmed: 2007457
J Crohns Colitis. 2017 Jan;11(1):84-91
pubmed: 27466171
J Biol Chem. 2004 Nov 19;279(47):48487-90
pubmed: 15337754
Cancer Sci. 2017 Oct;108(10):2052-2060
pubmed: 28746773

Auteurs

Tetsuhiro Yoshimura (T)

Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.
Inflammatory Bowel Disease Center, Kurume University Hospital, 67 Asahi-machi, Kurume 830-0011, Japan.

Keiichi Mitsuyama (K)

Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.
Inflammatory Bowel Disease Center, Kurume University Hospital, 67 Asahi-machi, Kurume 830-0011, Japan.

Ryosuke Sakemi (R)

Department of Gastroenterology, Tobata Kyoritsu Hospital, Kitakyushu, Japan.

Hidetoshi Takedatsu (H)

Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.
Inflammatory Bowel Disease Center, Kurume University Hospital, 67 Asahi-machi, Kurume 830-0011, Japan.

Shinichiro Yoshioka (S)

Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.
Inflammatory Bowel Disease Center, Kurume University Hospital, 67 Asahi-machi, Kurume 830-0011, Japan.

Kotaro Kuwaki (K)

Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.

Atsushi Mori (A)

Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.
Inflammatory Bowel Disease Center, Kurume University Hospital, 67 Asahi-machi, Kurume 830-0011, Japan.

Shuhei Fukunaga (S)

Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.
Inflammatory Bowel Disease Center, Kurume University Hospital, 67 Asahi-machi, Kurume 830-0011, Japan.

Toshihiro Araki (T)

Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.
Inflammatory Bowel Disease Center, Kurume University Hospital, 67 Asahi-machi, Kurume 830-0011, Japan.

Masaru Morita (M)

Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.
Inflammatory Bowel Disease Center, Kurume University Hospital, 67 Asahi-machi, Kurume 830-0011, Japan.

Kozo Tsuruta (K)

Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.
Inflammatory Bowel Disease Center, Kurume University Hospital, 67 Asahi-machi, Kurume 830-0011, Japan.

Hiroshi Yamasaki (H)

Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.

Takuji Torimura (T)

Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH